G. Lip, R. Hart, and D. Conway, Antithrombotic therapy in atrial fibrillation, Br. Med. J, vol.325, pp.1022-1047, 2002.
DOI : 10.1201/b14714-23

A. Camm, P. Kirchhof, G. Lip, and U. Schotten, European Association for Cardio-Thoracic Surgery Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the european society of cardiology (ESC), European Heart Rhythm Association, pp.2369-429, 2010.

C. Kearon, S. R. Kahn, G. Agnelli, S. Goldhaber, G. E. Raskob et al., Antithrombotic therapy for venous thromboembolic disease. (American College of Chest Physicians evidence-based clinical practice guidelines, pp.454-545, 2008.

A. Vahanian, Guidelines on the management of valvular heart disease: The task force on the management of valvular heart disease of the European Society of Cardiology

R. Hart, O. Benavente, R. Mc-bride, and L. Pearce, Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation, Annals of Internal Medicine, vol.131, issue.7, pp.492-501, 1999.
DOI : 10.7326/0003-4819-131-7-199910050-00003

C. Lagerstedt, C. Olsson, B. Fagher, B. Oquist, and V. Albrechtsson, NEED FOR LONG-TERM ANTICOAGULANT TREATMENT IN SYMPTOMATIC CALF-VEIN THROMBOSIS, The Lancet, vol.326, issue.8454, pp.515-533, 1985.
DOI : 10.1016/S0140-6736(85)90459-3

N. Holford, Clinical Pharmacokinetics and Pharmacodynamics of Warfarin, Clinical Pharmacokinetics, vol.11, issue.6, pp.483-504, 1986.
DOI : 10.2165/00003088-198611060-00005

J. Ansell, J. Hollowell, V. Pengo, F. Martinez-brotons, J. Caro et al., Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM), Journal of Thrombosis and Thrombolysis, vol.335, issue.Suppl, pp.83-91, 2007.
DOI : 10.1007/s11239-006-9022-7

M. Levine, G. Raskob, S. Landefeld, and C. Kearon, Hemorrhagic Complications of Anticoagulant Treatment, Chest, vol.119, issue.1, pp.108-129, 2001.
DOI : 10.1378/chest.119.1_suppl.108S

P. Pouyanne, F. Haramburu, J. Imbs, and B. Bégaud, Admissions to hospital caused by adverse drug reactions: cross sectional incidence study, BMJ, vol.320, issue.7241, p.1036, 2000.
DOI : 10.1136/bmj.320.7241.1036

L. Linkins, P. Choi, and J. Douketis, Clinical Impact of Bleeding in Patients Taking Oral Anticoagulant Therapy for Venous Thromboembolism, Annals of Internal Medicine, vol.139, issue.11, pp.893-900, 2003.
DOI : 10.7326/0003-4819-139-11-200312020-00007

B. Hutten, A. Lensing, R. Kraaijenhagen, and M. Prins, Safety of Treatment with Oral Anticoagulants in the Elderly, Drugs & Aging, vol.14, issue.4, pp.303-315, 1999.
DOI : 10.2165/00002512-199914040-00005

J. Ansell, J. Weitz, and A. Comerota, Advances in Therapy and the Management of Antithrombotic Drugs for Venous Thromboembolism, Hematology, vol.2000, issue.1, pp.266-84, 2000.
DOI : 10.1182/asheducation-2000.1.266

S. Fihn, C. Callahan, D. Martin, M. Mc-donell, J. Heniko et al., The Risk for and Severity of Bleeding Complications in Elderly Patients Treated with Warfarin, Annals of Internal Medicine, vol.124, issue.11, pp.970-979, 1996.
DOI : 10.7326/0003-4819-124-11-199606010-00004

G. Palareti and B. Cosmi, Bleeding with anticoagulation therapy ??? Who is at risk, and how best to identify such patients, Thrombosis and Haemostasis, vol.102, pp.268-78, 2009.
DOI : 10.1160/TH08-11-0730

A. Evans, S. Davis, C. Kilpatrick, R. Gerraty, D. Campbell et al., The morbidity related to atrial fibrillation at a tertiary centre in one year: 9.0% of all strokes are potentially preventable, Journal of Clinical Neuroscience, vol.9, issue.3, pp.268-72, 2002.
DOI : 10.1054/jocn.2001.1018

E. Hylek, Oral anticoagulants, Clinics in Geriatric Medicine, vol.17, issue.1, pp.1-13, 2002.
DOI : 10.1016/S0749-0690(05)70102-6

E. Hylek, S. Regan, A. Go, R. Hughes, D. Singer et al., Clinical Predictors of Prolonged Delay in Return of the International Normalized Ratio to within the Therapeutic Range after Excessive Anticoagulation with Warfarin, Annals of Internal Medicine, vol.135, issue.6, pp.393-400, 2001.
DOI : 10.7326/0003-4819-135-6-200109180-00008

D. Bonnet-zamponi, Heparin Bridging Therapy and Bleeding Events in Octogenarian Inpatients with Atrial Fibrillation Starting Anticoagulation: Results of an Ancillary Study, Journal of the American Geriatrics Society, vol.102, issue.6 Suppl
DOI : 10.1111/j.1532-5415.2011.03649.x

URL : https://hal.archives-ouvertes.fr/inserm-00707902

D. Warot, Beraprost sodium-fluindione combination in healthy subjects: pharmacokinetic and pharmacodynamic aspects, Fundamental & Clinical Pharmacology, vol.324, issue.3, pp.231-237, 2000.
DOI : 10.1111/j.1472-8206.2000.tb00021.x

K. Brendel, E. Comets, C. Laffont, C. Laveille, and F. Mentré, Metrics for External Model Evaluation with an Application to the Population Pharmacokinetics of Gliclazide, Pharmaceutical Research, vol.91, issue.9
DOI : 10.1007/s11095-006-9067-5

URL : https://hal.archives-ouvertes.fr/inserm-00189557

E. Comets, K. Brendel, and F. Mentré, Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: The npde add-on package for R, Computer Methods and Programs in Biomedicine, vol.90, issue.2
DOI : 10.1016/j.cmpb.2007.12.002

URL : https://hal.archives-ouvertes.fr/inserm-00274332

S. Fihn, Comparison of control and stability of oral anticoagulant therapy using acenocoumarol versus phenprocoumon, Thrombosis and Haemostasis, vol.90, pp.260-266, 2003.
DOI : 10.1160/TH02-10-0179

F. Mentré, Population pharmacokinetic-pharmacodynamic analysis of fluindione in patients*, Clinical Pharmacology & Therapeutics, vol.23, issue.1, pp.64-78, 1998.
DOI : 10.1016/S0009-9236(98)90122-9

E. Comets, Modeling INR Data to Predict Maintenance Fluindione Dosage, Therapeutic Drug Monitoring, vol.20, issue.6, pp.631-639, 1998.
DOI : 10.1097/00007691-199812000-00009

E. Comets, Prediction of Fluindione Maintenance Dosage Hampered by Large Intraindividual Variability, Therapeutic Drug Monitoring, vol.22, issue.6, pp.668-75, 2000.
DOI : 10.1097/00007691-200012000-00005

C. Verstuyft, A PK-PD model for predicting the impact of CYP2C9 and VKORC1 polymorphisms on fluindione and acenocoumarol during induction therapy, Clin. Pharmacol . Ther, 2011.

L. Benet and B. A. Hoener, Changes in plasma protein binding have little clinical relevance, Clinical Pharmacology & Therapeutics, vol.71, issue.3, pp.115-136, 2002.
DOI : 10.1067/mcp.2002.121829

G. Currie, J. Wheat, and H. Kiat, Pharmacokinetic Considerations for Digoxin in Older People, The Open Cardiovascular Medicine Journal, vol.5, issue.1, pp.130-135, 2011.
DOI : 10.2174/1874192401105010130

I. Mahé, A. S. Grenard, N. Joyeux, C. Caulin, and J. F. Bergmann, Management of oral anticoagulant in clinical practice: a retrospective study of 187 patients, J. Gerontol. A. Biol

T. Vogel, V. Coriol, G. Kaltenbach, M. Kiesmann, and M. Berthel, Difficult??s pour ??quilibrer les antivitamines K chez des personnes tr??s ??g??es hospitalis??es??: ??tude prospective chez 110 patients avec recherche de facteurs de risque de d??s??quilibre, La Presse M??dicale, vol.37, issue.12, pp.1723-1753, 2008.
DOI : 10.1016/j.lpm.2008.04.005

V. Siguret, C. Esquirol, M. Debray, I. Gouin, J. P. Andreux et al., Excess antivitamin k in elderly hospitalised patients aged over 70. a one-year prospective survey] [Article in French], Presse Med, vol.32, pp.972-979, 2003.

G. P. Aithal, C. P. Day, P. J. Kesteven, and A. K. Daly, Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications, The Lancet, vol.353, issue.9154, pp.717-726, 1999.
DOI : 10.1016/S0140-6736(98)04474-2

C. Verstuyft, Genetic and environmental risk factors for oral anticoagulant overdose, European Journal of Clinical Pharmacology, vol.ed, issue.11
DOI : 10.1007/s00228-002-0538-2

H. Lévesque and J. Y. Borg, Les centres de suivi et de conseil des traitements anticoagulants??: un outil pour diminuer le nombre de complications h??morragiques des antivitamines K, La Revue de M??decine Interne, vol.24, issue.2, pp.75-82, 2003.
DOI : 10.1016/S0248-8663(02)00019-X

C. Manotti, . Moia, G. Palareti, V. Pengo, L. Ria et al., Effect of computer-aided management on the quality of treatment in anticoagulated patients: a prospective, randomized, multicenter trial of APROAT (Automated Program for Oral Anticoagulant Treatment)

S. Rost, Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2, Nature, vol.427, issue.6974, pp.537-578, 2004.
DOI : 10.1038/nature02214

L. Bodin, Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity, Blood, vol.106, issue.1, pp.135-175, 2005.
DOI : 10.1182/blood-2005-01-0341

A. Levey, A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation, Annals of Internal Medicine, vol.130, issue.6, pp.461-70, 1999.
DOI : 10.7326/0003-4819-130-6-199903160-00002

A. M. Holbrook, Systematic Overview of Warfarin and Its Drug and Food Interactions, Archives of Internal Medicine, vol.165, issue.10, pp.1095-106, 2005.
DOI : 10.1001/archinte.165.10.1095

M. Lavielle and . Monolix, MOdèles NOn LInéairesLInéairesà effets miXtes). MONOLIX group, 2005.

R. Development and C. Team, R: A language and environment for statistical computing. R Foundation for Statistical Computing, 2004.

M. Karlsson and R. Savic, Diagnosing Model Diagnostics, Clinical Pharmacology & Therapeutics, vol.23, issue.1, pp.17-20, 2007.
DOI : 10.1038/sj.clpt.6100241

R. Little and D. Rubin, Statistical analysis with missing data, 2002.
DOI : 10.1002/9781119013563

G. Aymard, M. Legrand, E. Comets, F. Mentré, and B. Diquet, Rapid and simple micromethod for the quantification of fluindione in human plasma using high-performance liquid chromatography, Journal of Chromatography B: Biomedical Sciences and Applications, vol.707, issue.1-2, pp.169-173, 1998.
DOI : 10.1016/S0378-4347(97)00587-2

M. J. Rieder, Haplotypes on Transcriptional Regulation and Warfarin Dose, New England Journal of Medicine, vol.352, issue.22, pp.2285-93, 2005.
DOI : 10.1056/NEJMoa044503

K. Lacut, Vitamin K epoxide reductase genetic polymorphism is associated with venous thromboembolism: results from the EDITH Study, Journal of Thrombosis and Haemostasis, vol.128, issue.10, pp.2020-2024, 2007.
DOI : 10.1532/IJH97.06082

URL : https://hal.archives-ouvertes.fr/hal-00688300